AVCT Avacta Group Plc

TIDMAVCT

Avacta Group PLC

29 September 2014

29 September 2014

Avacta Group plc

("Avacta" or the "Group")

Investor Results Briefing

Avacta Group plc (AIM: AVCT), the global provider of proprietary diagnostic tools, consumables and reagents for human and animal healthcare, announces it will be hosting an investor results presentation on Thursday 16 October 2014 where Alastair Smith, CEO, Craig Slater, COO and Tim Sykes, CFO will present the Company's results for its financial year ended 31 July 2014.

The investor event, open to all investors, will be held from 16:30 at the Black Bar, Rocket, 6 Adams Court, EC2N 1DX followed by drinks and canapés.

For more information or to register to attend, contact Walbrook PR (contact details are below).

Enquiries:

 
 Avacta Group plc                                 Tel: +44 (0) 844 414 
  Alastair Smith, Chief Executive Officer          0452 
  Tim Sykes, Chief Financial Officer               www.avacta.com 
 
 Numis Securities Limited                         Tel: +44 (0) 207 260 
  Michael Meade / Freddie Barnfield - Nominated    1000 
  Adviser                                          www.numiscorp.com 
  James Black - Corporate Broking 
 
 Media Enquiries                                             Tel: +44 (0) 207 933 
  Walbrook PR Ltd                                             8780 
  Anna Dunphy / Mike Wort                                     avacta@walbrookpr.com 
 

About Avacta Group plc - www.avacta.com

Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics. Avacta operates through three divisions:

 
            Avacta Analytical             High throughput analysis instrument, Optim, 
             www.avactaanalytical.com      to help reduce the cost and risk of drug development. 
            Avacta Animal Health          Veterinary diagnostics reference laboratory, 
             www.avactaanimalhealth.com    diagnostic kits and newly launched in-clinic 
                                           blood analyser, Sensipod. 
                                         ------------------------------------------------------- 
            Avacta Life Sciences          Novel non-antibody affinity reagents called 
             www.avactalifesciences.com    Affimers, with a wide range of Life Science 
                                           applications in diagnostics, drug and biomarker 
                                           discover and biotech research and development. 
                                         ------------------------------------------------------- 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRASEAFMMFLSESU

Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2024 to May 2024

Avacta (LSE:AVCT)
Historical Stock Chart
From May 2023 to May 2024